Search

Displaying results 1051 - 1060 of 6949 in total
  1. Target

    Activin receptor type-2B

    go.drugbank.com/bio_entities/BE0010524
    TargetHumans

    Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor. … Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c).

    Polypeptides: Activin receptor type-2BSynonyms: Activin receptor type IIB
  2. Target

    Galanin receptor type 2

    go.drugbank.com/bio_entities/BE0011498
    TargetHumans

    Receptor for the hormone galanin and GALP. Receptor for the hormone spexin-1 (PubMed:24517231). … The activity of this receptor is mediated by G proteins that activate the phospholipase C/protein kinase C pathway (via G(q)) and that inhibit adenylyl cyclase (via G(i))

    Polypeptides: Galanin receptor type 2Function: galanin receptor activity
  3. Target

    Sigma intracellular receptor 2

    go.drugbank.com/bio_entities/BE0015084
    TargetHumans

    Sigma-2 receptor implicated in the regulation of multiple cellular processes, including cholesterol biosynthesis and trafficking, membrane trafficking, autophagy, lipid membrane-associated protein trafficking

    Polypeptides: Sigma intracellular receptor 2Synonyms: Sigma2 receptor, Sigma-2 receptor
  4. Target

    Chemerin-like receptor 1

    go.drugbank.com/bio_entities/BE0019036
    TargetHumans

    Receptor for the chemoattractant adipokine chemerin/RARRES2 and for the omega-3 fatty acid derived molecule resolvin E1.

    Polypeptides: Chemerin-like receptor 1Synonyms: Chemokine-like receptor 1, G protein-coupled receptor DEZ
  5. Drug

    Indium In-111 chloride

    go.drugbank.com/drugs/DB09490
    Approved

    and for radiolabeling Zevalin (ibritumomab tiuxetan) in preparations used for radioimmunotherapy procedures. … Indium In-111 Chloride is a diagnostic radiopharmaceutical agent intended for radiolabeling OncoScint (satumomab pendetide) or ProstaScint (capromab pendetide) used for _in vivo_ diagnostic imaging procedures

    Mixtures: OCTREOSCAN FOR INJECTION, Kit for the Preparation of Indium In 111 Pentetreotide
  6. Drug

    Vitamin A

    go.drugbank.com/drugs/DB00162
    ApprovedInvestigationalNutraceuticalVet approved

    Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A i...

    Mixtures: For-2, TAMIPOOL FOR INJECTIONCategories: Tests for Fat Absorption, Anti-Acne Preparations for Topical Use
  7. Drug

    Icosapent

    go.drugbank.com/drugs/DB00159
    ApprovedInvestigationalNutraceutical

    It serves as the precursor for the prostaglandin-3 and thromboxane-3 families.

    Mixtures: Se-Tan DHA, Se-Tan DHA
  8. Drug

    Vitamin E

    go.drugbank.com/drugs/DB00163
    ApprovedInvestigationalNutraceuticalVet approved

    Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label]. … The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory

    Mixtures: For-2, Multi-force for Women Tab
  9. Drug

    Manganese cation

    go.drugbank.com/drugs/DB06757
    ApprovedInvestigationalNutraceutical

    [A263687, A263662] In humans, manganese regulates several physiological processes by acting as a cofactor for proteins [A263657, A263662, A263667] making it an essential metal for normal development and

    Mixtures: Se-Tan PLUS, For-2
  10. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [A235174] On May 28, 2021, the FDA granted accelerated approval to infigratinib - under the market name Truseltiq - for the treatment of previously treated, unresectable locally advanced or metastatic … [L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment

    Categories: Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors, Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors